Start-up skincare company La Lumiere, LLC, creator of the innovative illuMask®, the world's first wearable light therapy mask, announced today that it has secured a $20 million Series B financing.  The investment included Johnson & Johnson Development Corporation (JJDC), the venture capital subsidiary of Johnson & Johnson, joining SWaN & Legend Venture Partners as institutional investors in the company.  The Series B investment is a culmination of efforts over the last 12 months to drive commercialization in the U.S and continued growth.

La Lumiere was founded on bringing innovations to the market for at-home beauty treatments.  As a leader in an emerging field of wearable light therapy devices, La Lumiere has two products currently on the market: one for anti-aging and the other for anti-acne.  "This was an attractive investment for us because of the incredible growth in the market for at-home beauty treatments.  La Lumiere is the leader in an emerging field and the only wearable light therapy device with strong intellectual property", said Todd Klein, CIO of Swan and Legend. 

Phototherapy is an effective skin care technology that uses safe wavelengths of light (non-UV) to treat skin conditions. For decades, light therapy treatments have been used by top dermatologists, spas and skin care clinics. IlluMask's innovative design uses a similar technology, with low level LED lights, to treat the entire face, making it possible to achieve affordable cosmetic results, safe and easily at home. Red light helps to even skin tone and reduces roughness while infrared light reduces the appearance of fine lines and wrinkles, resulting in visibly brighter and clearer skin.

illuMask light theraphy Mask. (source: illuMask)

La Lumiere estimates the market is currently worth $800 million and is expected to reach several billion dollars over the coming decade. Additionally, LED therapy is clinically proven to dramatically improve the quality of life of its users, and La Lumiere's illuMask® makes it more accessible to consumers across the country.

"This funding will help our technologies to reach exponentially more people," said Jay Tapper, Founder and CEO of La Lumiere, LLC and the illuMask® brand. "We're confident in the market potential, La Lumiere's intellectual property and our numerous competitive advantages."

La Lumiere plans to use the new capital to advance marketing and distribution, including a substantial advertising campaign for illuMask®, as well as funding their R&D pipeline of upcoming innovations. The illuMask® products were first introduced to the market in February 2014, and they are currently available in major mass market retailers, including Walmart, Target and Ulta.  illuMask® has been endorsed by Lucky, Elle, Cosmopolitan, Allure, Health, Fitness and other magazines.

To learn more please visit www.illuMask.com.